Skip to main content
Erschienen in: World Journal of Surgery 3/2011

01.03.2011

Impact of PET-CT on Primary Staging and Response Control on Multimodal Treatment of Esophageal Cancer

verfasst von: Kirsten Thurau, Daniel Palmes, Christiane Franzius, Evgeny Minin, Norbert Senninger, Kai Uwe Juergens, Matthias Bruewer

Erschienen in: World Journal of Surgery | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

The predictive value of positron emission tomography-computed tomography (PET-CT) in primary staging and response control in patients with esophageal carcinoma (EC) is under discussion. In the present study initial staging and metabolic response of PET-CT was correlated with tumor regression and survival in patients with multimodal treatment of EC.

Methods

The authors conducted a retrospective analysis on a prospective database for 83 patients with EC (42 squamous cell, 39 adenocarcinoma, 2 anaplastic carcinoma) undergoing PET-CT for primary staging. Twenty-four of the patients underwent primary esophagectomy, 9 had palliative treatment, and 50 neoadjuvant radiochemotherapy (cisplatin, 5-fluorouracil; 50.4 Gy). The PET-CT study was repeated 6 weeks after induction of chemotherapy and compared with endoscopic ultrasound (EUS). For response control, the metabolic response (tumor standardized uptake value [SUV] reduction) was correlated with histopathologic (ypT0-4) and histomorphologic response (tumor regression) and survival.

Results

At primary staging 81 of 83 EC (97.5%) showed an increased SUV uptake correlating with the EUS tumor stage. Suspicious lymph nodes were detected in 51 (61.4%) patients by PET-CT and 66 (79.5%) were detected by EUS. Fifteen patients had additional findings on PET-CT examination leading to a change in therapy in 9 patients (10.3%). Of 50 patients receiving a second PET-CT study, a SUV reduction >50% correlated with major histomorphologic response (tumor regression grade 4, <10% vital tumor cells) and histopathologic response (ypT0 ypN0). Furthermore, these patients showed a significantly increased survival (33.1 ± 3.5 months) compared to non-responders (21.7 ± 3.3 months; p = 0.02) and patients after primary surgery (29 ± 3.2 months; p = 0.05).

Conclusions

The present study shows that PET-CT is a valuable tool for primary staging and response control in multimodal treatment of patients with EC.
Literatur
1.
Zurück zum Zitat Stahl M, Stuschke M, Lehmann N et al (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 10:2310–2317CrossRef Stahl M, Stuschke M, Lehmann N et al (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 10:2310–2317CrossRef
2.
Zurück zum Zitat Bedenne L, Michel P, Bouché O et al (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25:1160–1168CrossRefPubMed Bedenne L, Michel P, Bouché O et al (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25:1160–1168CrossRefPubMed
3.
Zurück zum Zitat Schneider PM, Metzger R, Schaefer H et al (2008) Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for EC. Ann Surg 248:902–908CrossRefPubMed Schneider PM, Metzger R, Schaefer H et al (2008) Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for EC. Ann Surg 248:902–908CrossRefPubMed
4.
Zurück zum Zitat Sloof GW (2006) Response monitoring of neoadjuvant therapy using CT, EUS, and FDGPET. Best Pract Res Clin Gastroenterol 5:941–957CrossRef Sloof GW (2006) Response monitoring of neoadjuvant therapy using CT, EUS, and FDGPET. Best Pract Res Clin Gastroenterol 5:941–957CrossRef
5.
Zurück zum Zitat Williams RN, Ubhi SS, Sutton CD et al (2009) The early use of PET-CT alters the management of patients with esophageal cancer. J Gastrointest Surg 13:868–873CrossRefPubMed Williams RN, Ubhi SS, Sutton CD et al (2009) The early use of PET-CT alters the management of patients with esophageal cancer. J Gastrointest Surg 13:868–873CrossRefPubMed
6.
Zurück zum Zitat Noble F, Bailey D, SWCIS Upper Gastrointestinal Tumour Panel et al (2009) Impact of integrated PET/CT in the staging of oesophageal cancer: a UK population-based cohort study. Clin Radiol 64:699–705CrossRefPubMed Noble F, Bailey D, SWCIS Upper Gastrointestinal Tumour Panel et al (2009) Impact of integrated PET/CT in the staging of oesophageal cancer: a UK population-based cohort study. Clin Radiol 64:699–705CrossRefPubMed
7.
Zurück zum Zitat Roedl JB, Halpern EF, Colen RR et al (2009) Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus. Mol Imaging Biol 11:54–60CrossRefPubMed Roedl JB, Halpern EF, Colen RR et al (2009) Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus. Mol Imaging Biol 11:54–60CrossRefPubMed
8.
Zurück zum Zitat Vallböhmer D, Hölscher AH, Dietlein M et al (2009) [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 6:888–894CrossRef Vallböhmer D, Hölscher AH, Dietlein M et al (2009) [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 6:888–894CrossRef
9.
Zurück zum Zitat Palmes D, Weilinghoff M, Colombo-Benkmann M et al (2007) Effect of pyloric drainage procedures on gastric passage and bile reflux after esophagectomy with gastric conduit reconstruction. Langenbecks Arch Surg 392:135–144CrossRefPubMed Palmes D, Weilinghoff M, Colombo-Benkmann M et al (2007) Effect of pyloric drainage procedures on gastric passage and bile reflux after esophagectomy with gastric conduit reconstruction. Langenbecks Arch Surg 392:135–144CrossRefPubMed
10.
Zurück zum Zitat Juweid ME, Cheson BD (2006) Positron-emission tomography and assessment of cancer therapy. N Engl J Med 5:496–50711CrossRef Juweid ME, Cheson BD (2006) Positron-emission tomography and assessment of cancer therapy. N Engl J Med 5:496–50711CrossRef
11.
Zurück zum Zitat Cerfolio RJ, Bryant AS, Ohja B et al (2005) The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with EC after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 129:1232–1241CrossRefPubMed Cerfolio RJ, Bryant AS, Ohja B et al (2005) The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with EC after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 129:1232–1241CrossRefPubMed
12.
Zurück zum Zitat Lowe VJ, Kemp BJ, Jack CR Jr et al (2005) Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with EC. Mol Imaging Biol 7:422–430CrossRefPubMed Lowe VJ, Kemp BJ, Jack CR Jr et al (2005) Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with EC. Mol Imaging Biol 7:422–430CrossRefPubMed
13.
Zurück zum Zitat Polkowski M (2009) Endosonographic staging of upper intestinal malignancy. Best Pract Res Clin Gastroenterol 23:649–661CrossRefPubMed Polkowski M (2009) Endosonographic staging of upper intestinal malignancy. Best Pract Res Clin Gastroenterol 23:649–661CrossRefPubMed
14.
Zurück zum Zitat Van Vliet EP, Heijenbrok-Kal MH, Hunink MG et al (2008) Staging investigations for EC: a meta-analysis. Br J Cancer 98:547–557CrossRefPubMed Van Vliet EP, Heijenbrok-Kal MH, Hunink MG et al (2008) Staging investigations for EC: a meta-analysis. Br J Cancer 98:547–557CrossRefPubMed
15.
Zurück zum Zitat Rosenbaum SJ, Stergar H, Antoch G et al (2006) Staging and follow-up of gastrointestinal tumors with PET-CT. Abdom Imaging 31:25–35CrossRefPubMed Rosenbaum SJ, Stergar H, Antoch G et al (2006) Staging and follow-up of gastrointestinal tumors with PET-CT. Abdom Imaging 31:25–35CrossRefPubMed
16.
Zurück zum Zitat Cerfolio RJ, Bryant AS (2006) Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg 2:391–394CrossRef Cerfolio RJ, Bryant AS (2006) Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg 2:391–394CrossRef
17.
Zurück zum Zitat Rizk NP, Tang L, Adusumilli PS et al (2009) Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol 7:875–879CrossRef Rizk NP, Tang L, Adusumilli PS et al (2009) Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol 7:875–879CrossRef
18.
Zurück zum Zitat Salavati A, Basu S, Heidari P et al (2009) Impact of fluorodeoxyglucose PET on the management of EC. Nucl Med Commun 30:95–116CrossRefPubMed Salavati A, Basu S, Heidari P et al (2009) Impact of fluorodeoxyglucose PET on the management of EC. Nucl Med Commun 30:95–116CrossRefPubMed
19.
Zurück zum Zitat Antoch G, Saoudi N, Kuehl H et al (2004) Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET-CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 21:4357–4368CrossRef Antoch G, Saoudi N, Kuehl H et al (2004) Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET-CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 21:4357–4368CrossRef
20.
Zurück zum Zitat Swisher SG, Maish M, Erasmus JJ et al (2004) Utility of PET, CT, and EUS to identify pathologic responders in EC. Ann Thorac Surg 4:1152–1160CrossRef Swisher SG, Maish M, Erasmus JJ et al (2004) Utility of PET, CT, and EUS to identify pathologic responders in EC. Ann Thorac Surg 4:1152–1160CrossRef
21.
Zurück zum Zitat Song SY, Kim JH, Ryu JS et al (2005) FDG/PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable EC. Int J Radiat Oncol Biol Phys 4:1053–1059 Song SY, Kim JH, Ryu JS et al (2005) FDG/PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable EC. Int J Radiat Oncol Biol Phys 4:1053–1059
22.
Zurück zum Zitat Klaeser B, Nitzsche E, Schuller JC et al (2009) Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center. Onkologie 12:724–730CrossRef Klaeser B, Nitzsche E, Schuller JC et al (2009) Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center. Onkologie 12:724–730CrossRef
23.
Zurück zum Zitat Geh JI, Bond SJ, Bentzen SM et al (2006) Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol 3:236–244CrossRef Geh JI, Bond SJ, Bentzen SM et al (2006) Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol 3:236–244CrossRef
24.
Zurück zum Zitat De Manzoni G, Pedrazzani C, Laterza E et al (2005) Induction chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus: impact of increased dosage on long-term results. Ann Thorac Surg 4:1176–1183CrossRef De Manzoni G, Pedrazzani C, Laterza E et al (2005) Induction chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus: impact of increased dosage on long-term results. Ann Thorac Surg 4:1176–1183CrossRef
25.
Zurück zum Zitat Flamen P, Van Cutsem E, Lerut A et al (2002) Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced EC. Ann Oncol 3:361–368CrossRef Flamen P, Van Cutsem E, Lerut A et al (2002) Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced EC. Ann Oncol 3:361–368CrossRef
26.
Zurück zum Zitat Kroep JR, Van Groeningen CJ, Cuesta MA et al (2003) Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer: a comparison of different analytical methods. Mol Imaging Biol 5:337–346CrossRefPubMed Kroep JR, Van Groeningen CJ, Cuesta MA et al (2003) Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer: a comparison of different analytical methods. Mol Imaging Biol 5:337–346CrossRefPubMed
27.
Zurück zum Zitat Wieder HA, Brücher BL, Zimmermann F et al (2004) Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 5:900–908CrossRef Wieder HA, Brücher BL, Zimmermann F et al (2004) Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 5:900–908CrossRef
28.
Zurück zum Zitat Levine EA, Farmer MR, Clark P et al (2006) Predictive value of 18-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced EC. Ann Surg 4:472–478CrossRef Levine EA, Farmer MR, Clark P et al (2006) Predictive value of 18-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced EC. Ann Surg 4:472–478CrossRef
29.
Zurück zum Zitat Ott K, Weber W, Siewert JR (2006) The importance of PET in the diagnosis and response evaluation of EC. Dis Esophagus 6:433–442CrossRef Ott K, Weber W, Siewert JR (2006) The importance of PET in the diagnosis and response evaluation of EC. Dis Esophagus 6:433–442CrossRef
30.
Zurück zum Zitat Lordick F, Ott K, Krause BJ et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 9:797–805CrossRef Lordick F, Ott K, Krause BJ et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 9:797–805CrossRef
31.
Zurück zum Zitat Mamede M, Abreu-E-Lima P, Oliva MR et al (2007) FDG-PET-CT tumor segmentation derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in EC: correlation with histopathology results. Am J Clin Oncol 4:377–388CrossRef Mamede M, Abreu-E-Lima P, Oliva MR et al (2007) FDG-PET-CT tumor segmentation derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in EC: correlation with histopathology results. Am J Clin Oncol 4:377–388CrossRef
Metadaten
Titel
Impact of PET-CT on Primary Staging and Response Control on Multimodal Treatment of Esophageal Cancer
verfasst von
Kirsten Thurau
Daniel Palmes
Christiane Franzius
Evgeny Minin
Norbert Senninger
Kai Uwe Juergens
Matthias Bruewer
Publikationsdatum
01.03.2011
Verlag
Springer-Verlag
Erschienen in
World Journal of Surgery / Ausgabe 3/2011
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-010-0946-x

Weitere Artikel der Ausgabe 3/2011

World Journal of Surgery 3/2011 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.